Results about: drug
Recent years have seen a paradigm shift in our understanding of gene activity and regulation. It is now clear that processing of primary transcripts as well as translational control open a myriad of opportunities for gene regulation, which are extensively used in virtually every human gene.
A bioinformatics analysis of pairing 64 drugs used to treat breast cancer allows researchers at IRB Barcelona to identify 10 previously untested combinations with potential to tackle resistance to breast cancer treatment.
In spite of the many drugs available to treat breast cancer, resistance continues to be a problem.
Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
Catalan biotech Iproteos has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
The spin-off, founded by two IRB Barcelona scientists leaders in the field of therapeutic peptides, Teresa Tarrago and Ernest Giralt, expect to begin clinical trials of the compound in 2016.
Endowed with € 5,000 in each of their two categories -Biotechnology and Chemistry- the Expoquimia R+D+I Awards were delivered yesterday during the World Chemical Summit Night as part of the Expoquimia Exhibit at the Fair of Barcelona grounds.